WebInnate Pharma SA recently announced the online publication in The Lancet Oncology of the results from the completed Phase 1 dose-escalation and expansion clinical trial of IPH4102 in advanced CTCL patients.The Lancet Oncology publication can be accessed here. “We are very pleased with the publication of our IPH4102 Phase I results in a top tier, peer … WebHollings Cancer Center - A National Cancer Institute Designated Cancer Center . Search. Patient Care. Become a Patient; Cancer Types; Cancer Treatments
IPH4102, a first-in-class anti-KIR3DL2 monoclonal ... - ScienceDirect
Web1 jun. 2024 · IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open … Web11 apr. 2024 · lacutamab will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable … small things to do for your gf
IPH4102, a monoclonal antibody directed against the immune …
Web15 jun. 2024 · DOSE-ESCALATION DATA SHOW favorable SAFETY PROFILE AND PROMISING CLINICAL ACTIVITY FOR IPH4102 Oral presentation on the dose-escalation part of a Phase I trial at the International Conference on ... Web12 jun. 2024 · IPH4102 is a humanized first-in-class anti-KIR3DL2 monoclonal antibody designed to deplete KIR3DL2-expressing cells via antibody-dependent cell-cytotoxicity (ADCC) and phagocytosis. Web12 jul. 2024 · IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma Carrie Van Der … highway thru hell episode season 11 episode 1